A serious question:
The MSB announcement in Nov 20 re: Novartis deal.
As the deal hadn’t closed - should have it been disclosed?
it made specific reference that the deal was subject to the Hart Scott Rodino law that is usually applicable to mergers and acquisitions so had a low probability to affect the deal outcome. Yet the release is nebulous that the deal has to meet “certain other conditions”. Considering Novartis is now actively considering its options it would seem “certain other conditions”
include passing the trial.
considering this isn’t referred to in the release, did it create a misinformed market?
-
- There are more pages in this discussion • 128 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$2.36 |
Change
-0.075(3.09%) |
Mkt cap ! $3.052B | |||
| Open | High | Low | Value | Volume |
| $2.40 | $2.42 | $2.34 | $4.916M | 2.065M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 24 | 62048 | $2.35 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.36 | 66689 | 48 |
View Market Depth
| Last trade - 14.05pm 07/08/2025 (20 minute delay) ? |
| MSB (ASX) Chart |